EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling

Yuan Chen iD, Fang Ma iD, Nicholas Jones iD, Rong Deng iD, Chunze Li iD, Chi-Chung Li iD

CPT: Pharmacometrics & Systems Pharmacology · 2024

DOI: 10.1002/psp4.13073 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Yuan Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mosunetuzumab is a CD3/CD20 bispecific antibody. As an on‐target effect, transient elevation of interleukin‐6 (IL‐6) occurs in early treatment cycles. A physiologically‐based pharmacokinetic (PBPK) model was developed to assess potential drug interaction caused by IL‐6 enzyme suppression on cytochrome P450 3A (CYP3A) during mosunetuzumab treatment. The model's performance in predicting IL‐6 CYP3A suppression and subsequent drug–drug interactions (DDIs) was verified using existing clinical data of DDIs caused by chronic and transient IL‐6 elevation. Sensitivity analyses were performed for a complete DDI risk assessment. The IL‐6 concentration‐ and time‐dependent CYP3A suppression during mosunetuzumab treatment was simulated using PBPK model with incorporation of in vitro IL‐6 inhibition data. At clinically approved doses/regimens, the DDI at maximum CYP3A suppression was predicted to be a midazolam maximum drug concentration in plasma (C max ) and area under the plasma drug concentration–time curve (AUC) ratio of 1.17 and 1.37, respectively. At the 95th percentile of IL‐6 concentration level or when gut CYP3A suppression was considered, the predicted DDI risk for mosunetuzumab remained low (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP3AAntineoplastic AgentsHumansInterleukin-6CytokinesDrug InteractionsCytochrome P-450 CYP3A InhibitorsModels, Biological

Substanzen

Cytochrome P-450 CYP3AInterleukin-6CytokinesAntineoplastic AgentsCytochrome P-450 CYP3A Inhibitors

Autor:innen und Institutionen

  • Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA.
  • Clinical Science, Genentech, Inc., South San Francisco, California, USA.
  • Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.

ORCID-Profile: Yuan Chen, Fang Ma, Nicholas Jones, Rong Deng, Chunze Li, Chi-Chung Li

Zitieren

APA

Chen, Y., Ma, F., Jones, N., Deng, R., Li, C., & Li, C. C. (2024). Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13073

Vancouver

Chen Y, Ma F, Jones N, Deng R, Li C, Li CC. Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13073

BibTeX
@article{Chen2024,
  author = {Chen, Yuan and Ma, Fang and Jones, Nicholas and Deng, Rong and Li, Chunze and Li, Chi-Chung},
  title = {Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  doi = {10.1002/psp4.13073}
}
Kostenlos starten →